Medical and molecular biophysical techniques as substantial tools in the era of mRNA-based vaccine technology.

Medical and molecular biophysical techniques as substantial tools in the era of mRNA-based vaccine technology.

Publication date: Jul 17, 2024

The COVID-19 pandemic prompted the advancement of vaccine technology using mRNA delivery into the host cells. Consequently, mRNA-based vaccines have emerged as a practical approach against SARS-CoV-2 owing to their inherent properties, such as cost-effectiveness, rapid manufacturing, and preservation. These features are vital, especially in resource-constrained regions. Nevertheless, the design of mRNA-based vaccines is intricately intertwined with the refinement of biophysical technologies, thereby establishing their high potential. The preparation of mRNA-based vaccines involves a sequence of phases combining medical and molecular biophysical technologies. Furthermore, their efficiency depends on the capability to optimize their positive attributes, thus paving the way for their subsequent preclinical and clinical evaluations. Using biophysical techniques, the characterization of nucleic acids extends from their initial formulation to their cellular internalization abilities and encapsulation in biomolecule complexes, such as lipid nanoparticles (LNPs), for designing mRNA-based LNPs. Furthermore, nanoparticles are subjected to a series of careful screening steps to assess their physical and chemical characteristics before achieving an optimum formulation suitable for preclinical and clinical studies. This review provides a comprehensive understanding of the fundamental role of biophysical techniques in the complex development of mRNA-based vaccines and their role in the recent success during the COVID-19 pandemic.

Concepts Keywords
Host Based
Mrna Biophysical
Nanoparticles Clinical
Paving Covid
Vaccine Formulation
Furthermore
Lnps
Molecular
Mrna
Nanoparticles
Pandemic
Preclinical
Technologies
Vaccine
Vaccines

Semantics

Type Source Name
disease VO vaccine
disease MESH COVID-19 pandemic
disease IDO host
disease VO effectiveness
disease VO manufacturing
disease VO efficiency
drug DRUGBANK Spinosad

Original Article

(Visited 1 times, 1 visits today)